Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin
Purpose The dose limiting toxicity of oxaliplatin (l-HOP) is neurotoxicity, which is characterized by an acute neuropathy and a clinically distinct chronic neuropathy. This randomized study evaluated if prolonged l-HOP infusion over the conventional l-HOP schedule was useful in reducing acute and po...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2008-01, Vol.61 (1), p.105-111 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 111 |
|---|---|
| container_issue | 1 |
| container_start_page | 105 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 61 |
| creator | Petrioli, Roberto Pascucci, Alessandra Francini, Edoardo Marsili, Stefania Sciandivasci, Angela Tassi, Rossana Civitelli, Serenella Tanzini, Gabriello Lorenzi, Marco Francini, Guido |
| description | Purpose
The dose limiting toxicity of oxaliplatin (l-HOP) is neurotoxicity, which is characterized by an acute neuropathy and a clinically distinct chronic neuropathy. This randomized study evaluated if prolonged l-HOP infusion over the conventional l-HOP schedule was useful in reducing acute and possibly chronic l-HOP induced neurotoxicity in colon and gastric cancer patients receiving l-HOP-based regimen as adjuvant chemotherapy.
Methods
Sixty-four patients were randomly assigned to group A (26 colon and 6 gastric cancer) and to group B (23 colon and 9 gastric cancer). Chemotherapy in both groups consisted of l-HOP 85 mg/m
2
i.v. only on day 1, with leucovorin 100 mg/m
2
i.v. as a 2-h infusion followed by bolus 5-fluorouracil (5-FU) 400 mg/m
2
/day and a 22-h infusion of 5-FU 600 mg/m
2
/day, repeated for two consecutive days every 2 weeks for a maximum of 12 cycles. Patients in group A received l-HOP as a continuous 6-h i.v. infusion, and patients in group B received l-HOP as the conventional 2-h i.v. infusion.
Results
The percentage of patients presenting with grade ≥2 neurotoxicity was statistically lower in group A than in group B (28.1% vs. 59.3%:
P
= 0.02). There was a statistically lower percentage of cycles with grade ≥2 neurotoxicity in group A (6.1%) than in group B (18.5%) (
P
|
| doi_str_mv | 10.1007/s00280-007-0454-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21256198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1355864521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-e5ad1c7fd6cb56bd750d2788c7b3de6efd1b1009e41fcea27d0476edd0abb0183</originalsourceid><addsrcrecordid>eNp1kc-KFDEQxoMo7rj6AF4kCHprrfzpTrc3WRwVBuei4K1JJ5XdDD2dMUm7uz6Jj2vaGRgQPOUj9auvivoIec7gDQNQbxMAb6EqsgJZy0o8ICsmBa-gleIhWYGQsqoVyAvyJKUdAEgmxGNywZTkXSP4ivz-gnMMOdx54_M9DY6ut5v19nslqU5U2938U0-Z5og677EoFyI96OyLTvTW5xtqwhgmqidLr3XK0Rtq9GQwvqOaxvId9v4XWprybP8OyLeBWu8cxsUvmRu084hpKYU7PfrDWOynp-SR02PCZ6f3knxbf_h69anabD9-vnq_qYwUkCustWVGOduYoW4Gq2qwXLWtUYOw2KCzbCi36lAyZ1BzZUGqBq0FPQzAWnFJXh99DzH8mDHlfu-TwXHUE4Y59ZzxumHdAr78B9yFOU5lt8KIGiRvRYHYETIxpBTR9Yfo9zre9wz6JbP-mFm_yCWzful5cTKehz3ac8cppAK8OgE6GT26clTj05nrOtl0XBWOH7lUStM1xvOG_5_-B1cYsWY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213504283</pqid></control><display><type>article</type><title>Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Petrioli, Roberto ; Pascucci, Alessandra ; Francini, Edoardo ; Marsili, Stefania ; Sciandivasci, Angela ; Tassi, Rossana ; Civitelli, Serenella ; Tanzini, Gabriello ; Lorenzi, Marco ; Francini, Guido</creator><creatorcontrib>Petrioli, Roberto ; Pascucci, Alessandra ; Francini, Edoardo ; Marsili, Stefania ; Sciandivasci, Angela ; Tassi, Rossana ; Civitelli, Serenella ; Tanzini, Gabriello ; Lorenzi, Marco ; Francini, Guido</creatorcontrib><description>Purpose
The dose limiting toxicity of oxaliplatin (l-HOP) is neurotoxicity, which is characterized by an acute neuropathy and a clinically distinct chronic neuropathy. This randomized study evaluated if prolonged l-HOP infusion over the conventional l-HOP schedule was useful in reducing acute and possibly chronic l-HOP induced neurotoxicity in colon and gastric cancer patients receiving l-HOP-based regimen as adjuvant chemotherapy.
Methods
Sixty-four patients were randomly assigned to group A (26 colon and 6 gastric cancer) and to group B (23 colon and 9 gastric cancer). Chemotherapy in both groups consisted of l-HOP 85 mg/m
2
i.v. only on day 1, with leucovorin 100 mg/m
2
i.v. as a 2-h infusion followed by bolus 5-fluorouracil (5-FU) 400 mg/m
2
/day and a 22-h infusion of 5-FU 600 mg/m
2
/day, repeated for two consecutive days every 2 weeks for a maximum of 12 cycles. Patients in group A received l-HOP as a continuous 6-h i.v. infusion, and patients in group B received l-HOP as the conventional 2-h i.v. infusion.
Results
The percentage of patients presenting with grade ≥2 neurotoxicity was statistically lower in group A than in group B (28.1% vs. 59.3%:
P
= 0.02). There was a statistically lower percentage of cycles with grade ≥2 neurotoxicity in group A (6.1%) than in group B (18.5%) (
P
< 0.001).
Conclusions
This study suggests that l-HOP as a continuous 6-h infusion is useful in preventing and reducing acute l-HOP induced neurotoxicity in patients with colon and gastric cancer receiving FOLFOX-4 regimen as adjuvant treatment.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-007-0454-3</identifier><identifier>PMID: 17429632</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Acute Disease ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer Research ; Colonic Neoplasms - drug therapy ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Infusions, Intravenous ; Leucovorin - administration & dosage ; Leucovorin - adverse effects ; Male ; Maximum Tolerated Dose ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neurotoxicity Syndromes - etiology ; Oncology ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - adverse effects ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Stomach Neoplasms - drug therapy ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>Cancer chemotherapy and pharmacology, 2008-01, Vol.61 (1), p.105-111</ispartof><rights>Springer-Verlag 2007</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-e5ad1c7fd6cb56bd750d2788c7b3de6efd1b1009e41fcea27d0476edd0abb0183</citedby><cites>FETCH-LOGICAL-c430t-e5ad1c7fd6cb56bd750d2788c7b3de6efd1b1009e41fcea27d0476edd0abb0183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-007-0454-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-007-0454-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19946927$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17429632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Petrioli, Roberto</creatorcontrib><creatorcontrib>Pascucci, Alessandra</creatorcontrib><creatorcontrib>Francini, Edoardo</creatorcontrib><creatorcontrib>Marsili, Stefania</creatorcontrib><creatorcontrib>Sciandivasci, Angela</creatorcontrib><creatorcontrib>Tassi, Rossana</creatorcontrib><creatorcontrib>Civitelli, Serenella</creatorcontrib><creatorcontrib>Tanzini, Gabriello</creatorcontrib><creatorcontrib>Lorenzi, Marco</creatorcontrib><creatorcontrib>Francini, Guido</creatorcontrib><title>Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
The dose limiting toxicity of oxaliplatin (l-HOP) is neurotoxicity, which is characterized by an acute neuropathy and a clinically distinct chronic neuropathy. This randomized study evaluated if prolonged l-HOP infusion over the conventional l-HOP schedule was useful in reducing acute and possibly chronic l-HOP induced neurotoxicity in colon and gastric cancer patients receiving l-HOP-based regimen as adjuvant chemotherapy.
Methods
Sixty-four patients were randomly assigned to group A (26 colon and 6 gastric cancer) and to group B (23 colon and 9 gastric cancer). Chemotherapy in both groups consisted of l-HOP 85 mg/m
2
i.v. only on day 1, with leucovorin 100 mg/m
2
i.v. as a 2-h infusion followed by bolus 5-fluorouracil (5-FU) 400 mg/m
2
/day and a 22-h infusion of 5-FU 600 mg/m
2
/day, repeated for two consecutive days every 2 weeks for a maximum of 12 cycles. Patients in group A received l-HOP as a continuous 6-h i.v. infusion, and patients in group B received l-HOP as the conventional 2-h i.v. infusion.
Results
The percentage of patients presenting with grade ≥2 neurotoxicity was statistically lower in group A than in group B (28.1% vs. 59.3%:
P
= 0.02). There was a statistically lower percentage of cycles with grade ≥2 neurotoxicity in group A (6.1%) than in group B (18.5%) (
P
< 0.001).
Conclusions
This study suggests that l-HOP as a continuous 6-h infusion is useful in preventing and reducing acute l-HOP induced neurotoxicity in patients with colon and gastric cancer receiving FOLFOX-4 regimen as adjuvant treatment.</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Leucovorin - administration & dosage</subject><subject>Leucovorin - adverse effects</subject><subject>Male</subject><subject>Maximum Tolerated Dose</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neurotoxicity Syndromes - etiology</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc-KFDEQxoMo7rj6AF4kCHprrfzpTrc3WRwVBuei4K1JJ5XdDD2dMUm7uz6Jj2vaGRgQPOUj9auvivoIec7gDQNQbxMAb6EqsgJZy0o8ICsmBa-gleIhWYGQsqoVyAvyJKUdAEgmxGNywZTkXSP4ivz-gnMMOdx54_M9DY6ut5v19nslqU5U2938U0-Z5og677EoFyI96OyLTvTW5xtqwhgmqidLr3XK0Rtq9GQwvqOaxvId9v4XWprybP8OyLeBWu8cxsUvmRu084hpKYU7PfrDWOynp-SR02PCZ6f3knxbf_h69anabD9-vnq_qYwUkCustWVGOduYoW4Gq2qwXLWtUYOw2KCzbCi36lAyZ1BzZUGqBq0FPQzAWnFJXh99DzH8mDHlfu-TwXHUE4Y59ZzxumHdAr78B9yFOU5lt8KIGiRvRYHYETIxpBTR9Yfo9zre9wz6JbP-mFm_yCWzful5cTKehz3ac8cppAK8OgE6GT26clTj05nrOtl0XBWOH7lUStM1xvOG_5_-B1cYsWY</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Petrioli, Roberto</creator><creator>Pascucci, Alessandra</creator><creator>Francini, Edoardo</creator><creator>Marsili, Stefania</creator><creator>Sciandivasci, Angela</creator><creator>Tassi, Rossana</creator><creator>Civitelli, Serenella</creator><creator>Tanzini, Gabriello</creator><creator>Lorenzi, Marco</creator><creator>Francini, Guido</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20080101</creationdate><title>Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin</title><author>Petrioli, Roberto ; Pascucci, Alessandra ; Francini, Edoardo ; Marsili, Stefania ; Sciandivasci, Angela ; Tassi, Rossana ; Civitelli, Serenella ; Tanzini, Gabriello ; Lorenzi, Marco ; Francini, Guido</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-e5ad1c7fd6cb56bd750d2788c7b3de6efd1b1009e41fcea27d0476edd0abb0183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Leucovorin - administration & dosage</topic><topic>Leucovorin - adverse effects</topic><topic>Male</topic><topic>Maximum Tolerated Dose</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neurotoxicity Syndromes - etiology</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Petrioli, Roberto</creatorcontrib><creatorcontrib>Pascucci, Alessandra</creatorcontrib><creatorcontrib>Francini, Edoardo</creatorcontrib><creatorcontrib>Marsili, Stefania</creatorcontrib><creatorcontrib>Sciandivasci, Angela</creatorcontrib><creatorcontrib>Tassi, Rossana</creatorcontrib><creatorcontrib>Civitelli, Serenella</creatorcontrib><creatorcontrib>Tanzini, Gabriello</creatorcontrib><creatorcontrib>Lorenzi, Marco</creatorcontrib><creatorcontrib>Francini, Guido</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Petrioli, Roberto</au><au>Pascucci, Alessandra</au><au>Francini, Edoardo</au><au>Marsili, Stefania</au><au>Sciandivasci, Angela</au><au>Tassi, Rossana</au><au>Civitelli, Serenella</au><au>Tanzini, Gabriello</au><au>Lorenzi, Marco</au><au>Francini, Guido</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>61</volume><issue>1</issue><spage>105</spage><epage>111</epage><pages>105-111</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Purpose
The dose limiting toxicity of oxaliplatin (l-HOP) is neurotoxicity, which is characterized by an acute neuropathy and a clinically distinct chronic neuropathy. This randomized study evaluated if prolonged l-HOP infusion over the conventional l-HOP schedule was useful in reducing acute and possibly chronic l-HOP induced neurotoxicity in colon and gastric cancer patients receiving l-HOP-based regimen as adjuvant chemotherapy.
Methods
Sixty-four patients were randomly assigned to group A (26 colon and 6 gastric cancer) and to group B (23 colon and 9 gastric cancer). Chemotherapy in both groups consisted of l-HOP 85 mg/m
2
i.v. only on day 1, with leucovorin 100 mg/m
2
i.v. as a 2-h infusion followed by bolus 5-fluorouracil (5-FU) 400 mg/m
2
/day and a 22-h infusion of 5-FU 600 mg/m
2
/day, repeated for two consecutive days every 2 weeks for a maximum of 12 cycles. Patients in group A received l-HOP as a continuous 6-h i.v. infusion, and patients in group B received l-HOP as the conventional 2-h i.v. infusion.
Results
The percentage of patients presenting with grade ≥2 neurotoxicity was statistically lower in group A than in group B (28.1% vs. 59.3%:
P
= 0.02). There was a statistically lower percentage of cycles with grade ≥2 neurotoxicity in group A (6.1%) than in group B (18.5%) (
P
< 0.001).
Conclusions
This study suggests that l-HOP as a continuous 6-h infusion is useful in preventing and reducing acute l-HOP induced neurotoxicity in patients with colon and gastric cancer receiving FOLFOX-4 regimen as adjuvant treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>17429632</pmid><doi>10.1007/s00280-007-0454-3</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2008-01, Vol.61 (1), p.105-111 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21256198 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Acute Disease Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Research Colonic Neoplasms - drug therapy Dose-Response Relationship, Drug Drug Administration Schedule Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Humans Infusions, Intravenous Leucovorin - administration & dosage Leucovorin - adverse effects Male Maximum Tolerated Dose Medical sciences Medicine Medicine & Public Health Middle Aged Neurotoxicity Syndromes - etiology Oncology Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Stomach Neoplasms - drug therapy Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
| title | Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurotoxicity%20of%20FOLFOX-4%20as%20adjuvant%20treatment%20for%20patients%20with%20colon%20and%20gastric%20cancer:%20a%20randomized%20study%20of%20two%20different%20schedules%20of%20oxaliplatin&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Petrioli,%20Roberto&rft.date=2008-01-01&rft.volume=61&rft.issue=1&rft.spage=105&rft.epage=111&rft.pages=105-111&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-007-0454-3&rft_dat=%3Cproquest_cross%3E1355864521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213504283&rft_id=info:pmid/17429632&rfr_iscdi=true |